Table 4 Results of cytology and HR-HPV co-testing
Cytological interpretation | HR-HPV testing | Total | ||||
|---|---|---|---|---|---|---|
HC2 testing | Genotyping | |||||
Negative (%) | Positive (%) | Negative (%) | Positive (%) | Negative (%) | Positive (%) | |
CIN1 (n = 556) | ||||||
 NILM | 3 (1.5) | 14 (7.2) | 23 (6.4) | 27 (7.5) | 26 (4.7) | 41 (7.4) |
 ASC-US | 20 (10.3) | 49 (25.3) | 40 (11.0) | 91 (25.1) | 60 (10.8) | 140 (25.2) |
 ASC-H | 2 (1.0) | 4 (2.1) | 3 (0.8) | 3 (0.8) | 5 (0.9) | 7 (1.3) |
 LSIL | 18 (9.3) | 79 (40.7) | 38 (10.5) | 130 (35.9) | 56 (10.1) | 209 (37.6) |
 HSIL | 3 (1.5) | 2 (1.0) | 1 (0.3) | 6 (1.7) | 4 (0.7) | 8 (1.4) |
Total | 46 (23.7) | 148 (76.3) | 105 (29.0) | 257 (71.0) | 151 (27.2) | 405 (72.8) |
CIN2/3 (n = 524) | ||||||
 NILM | 0 (0) | 12 (5.6) | 1 (0.3) | 25 (8.0) | 1 (0.2) | 37 (7.1) |
 ASC-US | 2 (0.9) | 33 (15.5) | 7 (2.3) | 53 (17.0) | 9 (1.7) | 86 (16.4) |
 ASC-H | 2 (0.9) | 35 (16.4) | 2 (0.6) | 22 (7.1) | 4 (0.8) | 57 (10.9) |
 LSIL | 4 (1.9) | 52 (24.4) | 6 (1.9) | 74 (23.8) | 10 (1.9) | 126 (24.0) |
 HSIL | 5 (2.3) | 68 (31.9) | 9 (2.9) | 112 (36.0) | 14 (2.7) | 180 (34.4) |
Total | 13 (6.1) | 200 (93.9) | 25 (8.0) | 286 (92.0) | 38 (7.3) | 486 (92.7) |
ICC (n = 230) | ||||||
 NILM | 0 (0) | 3 (7.3) | 1 (0.5) | 6 (3.2) | 1 (0.4) | 9 (3.9) |
 Unsatisfactory | 0 (0) | 0 (0) | 0 (0) | 5 (2.6) | 0 (0) | 5 (2.2) |
 ASC-US | 1 (2.4) | 3 (7.3) | 3 (1.6) | 15 (7.9) | 4 (1.7) | 18 (7.8) |
 ASC-H | 0 (0) | 10 (24.4) | 1 (0.5) | 29 (15.3) | 1 (0.4) | 39 (17.0) |
 LSIL | 0 (0) | 0 (0) | 0 (0) | 1 (0.5) | 0 (0) | 1 (0.4) |
 HSIL | 0 (0) | 18 (43.9) | 1 (0.5) | 100 (52.9) | 1 (0.4) | 118 (51.3) |
 AGC | 0 (0) | 0 (0) | 2 (1.1) | 3 (1.6) | 2 (0.9) | 3 (1.3) |
 Cancer cells | 0 (0) | 6 (14.6) | 3 (1.6) | 19 (10.1) | 3 (1.3) | 25 (10.9) |
Total | 1 (2.4) | 40 (97.6) | 11 (5.8) | 178 (94.2) | 12 (5.2) | 218 (94.8) |